Proton Pump

KR-60436 is a reversible inhibitor of H+/K+-ATPase, effectively obstructing proton and potassium transport across cellular membranes. This compound has demonstrated potent inhibition of CYP1A2 substrate metabolism, making it a valuable tool for studying gastric proton pump activity and its implications in drug metabolism. Its utility extends to drug interaction studies and the investigation of gastrointestinal pharmacology.

SKF96067 is a reversible inhibitor of the gastric H+/K+-ATPase, primarily targeting proton pumps involved in gastric acid secretion. This compound demonstrates significant biological activity in reducing gastric acid production, making it useful in research related to gastrointestinal diseases and acid-related disorders. Its modulation of proton pump activity aids in elucidating mechanisms of acid secretion regulation and the potential therapeutic effects on related pathologies.

Nepaprazole is a proton pump inhibitor that targets H+/K+-ATPase activity, significantly reducing gastric acid secretion. It demonstrates inhibitory effects in isolated rabbit gastric mucosal microsomes with IC50 values of 5.8 μM and 9.9 μM at pH 6.0 and pH 7.4, respectively. This compound is primarily utilized in research related to peptic ulcer diseases, providing insights into gastric acid regulation and potential therapeutic interventions.

Tenatoprazole sodium is a potent proton pump inhibitor that specifically targets the hog gastric H+/K+-ATPase, exhibiting an IC50 of 6.2 μM. This compound effectively decreases gastric acid secretion, making it valuable for research in gastrointestinal disorders and related therapeutic applications. Its mechanism of action positions it as a useful tool for studying the regulation of gastric acidity and the underlying pathways involved in acid-related diseases.

S3337 is a potent inhibitor of H+, K+-ATPase, a key enzyme responsible for regulating gastric acid secretion. By targeting this proton pump, S3337 effectively reduces gastric acid production, making it valuable for research into acid-related disorders. Its primary applications include studies on gastritis, peptic ulcers, and gastroesophageal reflux disease (GERD).

DBM-819 is a reversible inhibitor of H⁺/K⁺-ATPase, exhibiting an IC50 value of 5 µM. This compound effectively inhibits gastric acid secretion by blocking the proton pump in the gastric mucosa, demonstrating significant protective effects against duodenal ulcers induced by Cysteamine, and gastric ulcers induced by Indomethacin and Aspirin, with EC50 values of 6, 3.1, and 4 mg/kg, respectively. DBM-819 serves as a valuable tool in research focused on ulcer prevention and gastroprotection.

Ro 18-5364 is a selective inhibitor of gastric H+/K+ ATPase, primarily targeting the enzyme's activity. It demonstrates significant inhibition, particularly at lower pH levels, making it a valuable tool for studying gastric physiology. The compound's effects on enzyme activity, proton transport, and binding interactions can be assessed through various experimental methodologies, providing insights into its mechanism of action and potential therapeutic applications in conditions related to proton pump regulation.

A 80915A is a potent proton pump inhibitor derived from seminaphthoquinone, which is produced by the Streptomyces species. It functions primarily by inhibiting Na+/K+ ATPase, a key enzyme involved in gastric acid secretion. This compound is valuable for research applications focused on understanding gastrointestinal physiology and exploring therapeutic strategies for acid-related disorders.

Esomeprazole magnesium, a potent H+, K+-ATPase inhibitor, is utilized in research related to upper intestinal disorders and gastroesophageal reflux disease. Its primary mechanism involves the inhibition of proton pumps, leading to decreased gastric acid secretion. Additionally, Esomeprazole magnesium exhibits properties as an exosome inhibitor by blocking exosome release through the inhibition of vacuolar H+-ATPases, making it valuable for studies on cellular communication and disease progression.

Ilaprazole sodium is a potent proton pump inhibitor that irreversibly targets H+/K+-ATPase, demonstrating a dose-dependent inhibition with an IC50 of 6 μM in rabbit parietal cell assays. This compound is primarily utilized in research focused on gastric ulcers, providing insights into gastric acid secretion regulation. Additionally, Ilaprazole sodium acts as an effective inhibitor of TOPK (T-lymphokine-activated killer cell-originated protein kinase), facilitating studies related to immune responses and cancer therapeutics.

Azeloprazole is a proton pump inhibitor that targets the H+,K+-ATPase enzyme, effectively reducing gastric acid secretion. It has demonstrated significant efficacy in preclinical models, including a dog's gastric fistula, where it outperformed esomeprazole in terms of duration of action. This compound is useful in studying acid-related diseases and exploring mechanisms of gastric acid regulation.